Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Acute Myeloid Leukemia Clinical Trial

— VHA  

Official title:

Venetoclax in Combination With Homoharringtonine and Cytarabine in Newly Diagnosed Subjects With Acute Myeloid Leukemia: a Phase 2/3, the Single-arm, Open-label, Monocentric Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05805098
• Other study ID #: SZQ001
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: March 1, 2023
• Est. completion date: March 1, 2028

Study information

• Verified date: March 2023
• Source: The First Affiliated Hospital of Soochow University
• Contact: Huiying Qiu, PhD
• Phone: 13912792913
• Email: qiuhuiying[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.

Description:

This is a phase II/III study that seeks to treat patients ages 18-60 who have acute myeloid leukemia but have never been treated before. In order to improve the outcome of patients with primary AML, venetoclax combined with homoharringtonine and cytarabine was applied in the treatment of primary AML. This study aims to evaluate the efficacy and safety of venetoclax in combination with homoharringtonine and cytarabine in newly diagnosed subjects with AML.Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant. After completion of study treatment, participants are followed up every 3 to 6 months for up to 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 1, 2028
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.

2. patients must have confirmation of AML by WHO criteria, previously untreated, and eligible for treatment with intensive chemotherapy as defined by the following: Cardiac history of congestive heart failure requiring treatment or ejection fraction = 50% or chronic stable angina. Diffusing capacity of the lung for carbon monoxide (DLCO) = 65% or forced expiratory volume during the first second (FEV1) = 65%. Creatinine clearance < 45 mL/min. Moderate hepatic impairment with total bilirubin > 1.5 × ULN. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy.

3. Patients > 18 to = 60 years

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of =2

5. Laboratory values meeting the following criteria:Creatinine clearance = 45 mL/min calculated by the Cockcroft Gault formula or measured by 24-hour urine collection, Serum aspartate aminotransferase (AST) = 3.0 × upper limit of normal (ULN) ?Serum alanine aminotransferase (ALT) = 3.0 × ULN (Unless considered due to leukemic organ involvement), Total bilirubin = 1.5 × ULN, White blood cell (WBC) count < 25 × 109 /L (hydroxyurea is permitted to meet this criterion)

Exclusion Criteria:

1. > 60 years of age or <18 years of age

2. Acute promyelocytic leukemia (M3)

3. Patient is ineligible for treatment with intensive chemotherapy

4. Patient with active infection not controlled, active bleeding from vital organs

5. Patient with history of clinically significant drug or alcohol abuse that would adversely affect evaluation in this study

6. Patient has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study.

7. Female who are pregnant, breast feeding or childbearing potential without a negative urine pregnancy test at screen.

8. Patients with uncontrolled infection with human immunodeficiency virus (HIV) or active Hepatitis B or C

9. Patients deemed unsuitable for enrolment by the investigator.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Venetoclax
Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
• Homoharringtonine
On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
• Cytarabine
On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.

Locations

Country	Name	City	State
China	Qiu Huiying	Suzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR)	Defined as complete response (CR) + CR with incomplete blood count recovery (CRi) + morphologic leukemia-free state (MLFS) + partial response (PR).	28 days after study treatment
Secondary	Rate of Participants With Adverse Events	Percentage of Participants with 3 or 4 grade Adverse Events reported through 28 days post study medication administration.	Through 28 days post study medication administration
Secondary	Event-free survival	Defined as the number of days from the date of treatment initiation (i.e., course 1 day 1) to the date of documented treatment failure, relapses from CR, or death from any cause, whichever occurs first. Will be calculated for all patients. Estimated using Kaplan-Meier method. Log-rank tests will be used to compare among subgroups of patients.	Through study completion, up to 3 years
Secondary	Overall survival	Estimated using Kaplan-Meier method. Log-rank tests will be used to compare among subgroups of patients.	Through study completion, up to 3 years